Nf-kb inhibitors
Nf-kb inhibitors has been studied in 4 papers since 2022: none in people yet, 3 in cells, 1 review. No study of it in people or animals has been published yet. The newest paper, Mar 7, 2025: “The influence of senescent associated secretory phenotype on glucose homeostasis in C2C12 muscle cells: insights into potential p38 inhibitor interventions”.
4 papers study it3 findingsUpdated
- 2 independent labs in 2 countries
- Funder: Aston University
- Cells3
What did studies of Nf-kb inhibitors find?
3Studies of Nf-kb inhibitors measured 3 outcomes; the most studied are reactive oxygen species (1 study), glucose utilization (1) and differentiation potential (1).
Reactive oxygen species
downin mouse cells1
1 study
Reactive oxygen species
downin mouse cells1
Nf-kb inhibitors decrease reactive oxygen species in mouse cells.
“Co-incubation of 40% SASP with an NF-κβ inhibitor eliminates excessive reactive oxygen species production and restored mitochondrial density to levels comparable to control treatment.”
Cellsin C2C12 myotubes with 40% SASP
Research SquarePreprint
Glucose utilization
upin mouse cells1
1 study
Glucose utilization
upin mouse cells1
Nf-kb inhibitors improve glucose utilization in mouse cells (p = < 0.01).
“Blocking NF-κβ, the pro-inflammatory signalling cascade restored glucose utilisation (p = < 0.01) despite the presence of 40% SASP.”
Cellsin C2C12 myotubes in the presence of 40% SASP
Research SquarePreprint
Differentiation potential
upin cells1
1 study
Differentiation potential
upin cells1
Nf-kb inhibitors improve differentiation potential in cells.
“Similar changes could also be achieved by using an inhibitor of NF-κB signaling”
Cellsin aged MSCs
Stem cells and development